Diarrhea on Wegovy (semaglutide 2.4 mg): Incidence, Severity, and Realistic Expectations

How common is diarrhea on Wegovy?

The most-quoted number comes from the label's pooled safety analysis: three randomized, double-blind, placebo-controlled trials covering 2,116 adults on Wegovy 2.4 mg injection for up to 68 weeks and 1,261 on placebo, with a mean age of 48 and 71% women [1]. In that set, diarrhea was reported by 30% of Wegovy-treated adults and 16% of placebo-treated adults [1].

Nausea was more common still, at 44% versus 16%, and vomiting (24% vs 6%) and constipation (24% vs 11%) landed in the same range as diarrhea [1]. Abdominal pain was reported by 20% versus 10% [1]. Taken together, 73% of people on Wegovy reported at least one GI reaction versus 47% on placebo [1].

For context, a 2024 JAMA review of obesity medications put diarrhea across liraglutide, semaglutide and tirzepatide at 21% to 30% [2].

How severe is it, and how often does it stop treatment?

Two label figures answer this. Severe gastrointestinal reactions occurred in 4.1% of Wegovy-treated adults versus 0.9% on placebo [1]. And 6.8% of people on Wegovy stopped treatment for any adverse reaction versus 3.2% on placebo; the diarrhea-specific numbers were 0.7% versus 0.1% [1].

Nausea (1.8% vs 0.2%) and vomiting (1.2% vs 0%) were each more frequent reasons for stopping than diarrhea [1].

Individual trials track the same way. In STEP 1, which randomized 1,961 adults without diabetes to semaglutide 2.4 mg or placebo for 68 weeks, 4.5% of the semaglutide group stopped for GI events versus 0.8% on placebo [3]. In STEP 5, a 104-week trial of 304 adults, GI adverse events were reported by 82.2% on semaglutide and 53.9% on placebo, and were mostly mild to moderate [4].

Timing and dose escalation

Wegovy injection steps up every four weeks: 0.25 mg for weeks 1 to 4, then 0.5 mg, 1 mg and 1.7 mg, with maintenance from week 17, usually at 2.4 mg [1]. Adults who tolerate 2.4 mg for at least four weeks and need more weight loss can go to 7.2 mg [1].

The label's safety table reports one diarrhea rate for the whole treatment period rather than a separate rate for each titration step [1]. We found no published breakdown of Wegovy diarrhea rates by dose step. In the two 72-week trials comparing 7.2 mg, 2.4 mg and placebo, 3% of people on 7.2 mg and 3% on 2.4 mg stopped for GI reasons, versus 0.3% on placebo [1].

Dehydration and kidney risk: what the label says

The Wegovy label carries a warning for acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the weight-management trials, kidney injury occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, and often after fluid loss from GI symptoms [1].

The same warnings section says Wegovy is not recommended in patients with severe gastroparesis, and the postmarketing reports listed in the label include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

Tablets, children, and other semaglutide products

Wegovy 25 mg daily tablets were tested in one 64-week trial of 204 adults, and the label says reaction types and frequencies were similar to the injection table, with severe GI reactions in 2% versus 0% on placebo [1]. In the adolescent trial (133 on Wegovy, 67 on placebo, 68 weeks), diarrhea was reported by 22% versus 19% [1].

What is not established

The label gives no average episode length, and we found no published figure for how long a single bout of Wegovy-related diarrhea lasts or what share of cases settle without a dose change.